| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 05-13-2024 | 03-31-2024 | 10-Q | |
| 2 | 03-29-2024 | 12-31-2023 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects...
Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal...
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases ...
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telo...
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical c...
